Literature DB >> 23929652

Juvenile nasopharyngeal angiofibroma: vascular determinates for operative complications and tumor recurrence.

Kenny H Chan1, Dexiang Gao, Patrick G Fernandez, Todd T Kingdom, David A Kumpe.   

Abstract

OBJECTIVES/HYPOTHESIS: Operative complications and tumor recurrence in juvenile nasopharyngeal angiofibroma (JNA) are measurable and meaningful outcomes. This study aimed to assess the association of these two outcomes to various clinical indices and in particular, vascular determinates. STUDY
DESIGN: Retrospective cohort study.
METHODS: An 18-year retrospective chart review of an academic tertiary center was undertaken. Data from clinical notes, imaging studies, and arteriograms were analyzed.
RESULTS: Thirty-seven male (mean age, 14.4 years) patients were included in the study. Tumor stages included: IA (three), IB (three), IIA (14), IIB (three), IIC (five), IIIA (five), and IIIB (four). Four complications (cerebrospinal fluid leak, cerebral vascular accident, and two transient ocular defects) occurred. Eight recurrences occurred within 24 months following surgery. Complications were associated with estimated intraoperative blood loss (EBL) (P = .045). Tumor recurrence was associated with feeding vessels from the contralateral internal carotid artery (ICA) (P = .017). EBL was significantly associated with surgical technique used. EBL, tumor stage, and tumor vascular supply were significantly associated with each other.
CONCLUSIONS: Vascular factors were associated with JNA complication and tumor recurrence. EBL might affect complications, and contralateral ICA as a feeding vessel might affect recurrence. EBL was influenced by procedure choice and was interrelated to size and vascular supply of the tumor. This study bolsters the need to decrease intraoperative blood loss by preoperative embolization and use of endoscopic removal techniques. Furthermore, when branches of the ICA are found to be feeding vessels, greater surgical attention for a dry surgical field is encouraged.
© 2013 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Nasopharynx; head and neck (malignancy); nasopharyngeal angiofibroma

Mesh:

Year:  2013        PMID: 23929652     DOI: 10.1002/lary.24337

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Role of Transarterial Angiography with Embolization in Deciding Surgical Approach to Juvenile Nasopharyngeal Angiofibroma: A Step-Ladder Approach.

Authors:  Ravi S Manogaran; Arulalan Mathialagan; Vivek Singh; Prabhaker Mishra; Rajat Jain; Amit Keshri
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-20

2.  Association between vascular supply, stage and tumour size of juvenile nasopharyngeal angiofibroma.

Authors:  Raghav Mehan; V Rupa; Vijay Kumar Lukka; Munawar Ahmed; Vinu Moses; N K Shyam Kumar
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-11       Impact factor: 2.503

3.  Recurrence Rate after Endoscopic vs. Open Approaches for Juvenile Nasopharyngeal Angiofibroma: A Meta-analysis.

Authors:  Camilo Reyes; Heather Bentley; J Alejandro Gelves; C Arturo Solares; J Kenneth Byrd
Journal:  J Neurol Surg B Skull Base       Date:  2018-12-26

4.  Differential Gene Expression and Pathway Analysis in Juvenile Nasopharyngeal Angiofibroma Using RNA Sequencing.

Authors:  Joel W Jones; Shireen Usman; Jacob New; Andrew Holcomb; Sumedha Gunewardena; Ossama Tawfik; Larry Hoover; Daniel Bruegger; Sufi Mary Thomas
Journal:  Otolaryngol Head Neck Surg       Date:  2018-04-10       Impact factor: 3.497

5.  Imaging of Unilateral Meningo-ophthalmic Artery Anomaly in a Patient with Bilateral Nasopharyngeal Angiofibroma.

Authors:  Louise Louw; Johan Steyl; Eugene Loggenberg
Journal:  J Clin Imaging Sci       Date:  2014-11-29

6.  The Endovascular Treatment of Epistaxis.

Authors:  S Nicolay; T Van Der Zijden; M Voormolen; O d'Archambeau; J Maes; F De Belder; P M Parizel
Journal:  J Belg Soc Radiol       Date:  2015-12-30       Impact factor: 1.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.